Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Phi Health launches high-performance MRI system at RSNA 2009

Phi Health, a healthcare technology company, announced at the RSNA 2009 Annual Meeting in Chicago, IL, November 29, 2009 – December 4, 2009, that it is introducing Memex, a proprietary high-performance, yet low-cost 1.5T MRI system.

1 Dec 2009

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

MICARDIS(R) (telmisartan) has received Health Canada approval to reduce the risk of non-fatal stroke or non-fatal myocardial infarction in patients 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme (ACE) inhibitor.

26 Nov 2009

Vitamin D deficiency may increase risk of stroke, heart disease and death, finds study

While mothers have known that feeding their kids milk builds strong bones, a new study by researchers at the Heart Institute at Intermountain Medical Center in Salt Lake City suggests that Vitamin D contributes to a strong and healthy heart as well - and that inadequate levels of the vitamin may significantly increase a person's risk of stroke, heart disease, and death, even among people who've never had heart disease.

24 Nov 2009

New MEMS sensor may help clinicians distinguish stable and unstable plaque during cardiac emergencies

University of Sourthern California biomedical engineer and cardiologist Tzung "John" Hsiai hopes to develop a new tool to help clinicians distinguish cardiac emergencies requiring immediate surgery from chronic problems manageable with drugs and lifestyle change.

24 Nov 2009

Vitamin D: A multi-purpose nutrient for overall health

A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic."

24 Nov 2009

Review of study presented at American Heart Association Scientific Sessions

Adding the cholesterol drug niacin to a statin improved HDL ("good") cholesterol levels and significantly reduced carotid arterial plaque buildup measured with ultrasound within 8 months, with further improvement seen at the end of the study (14 months).

21 Nov 2009

Dual niacin-statin therapy improves blood cholesterol levels but does not diminish plaque buildup

The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows.

19 Nov 2009

Key findings from AstraZeneca's phase II studies of ticagrelor

AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA(TM)) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL,with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation.

18 Nov 2009

Clinical Data commences patient enrollment in Stedivaze Phase III trial

Clinical Data, Inc. today announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze™, a potential best-in-class vasodilator for use in cardiac stress testing. The study will evaluate the safety and efficacy of Stedivaze (apadenoson) for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI), a method for detecting defects in the blood supply to the heart.

18 Nov 2009

First gene expression test for coronary artery disease

The Heart & Vascular Center of Arizona today announced the availability of Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(i) coronary artery disease (CAD) in patients with stable chest pain.

18 Nov 2009

Aterovax presents results of its sPLA2 activity test in the PEACE trial

Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.

17 Nov 2009

Statin therapy should still be used first to reach blood cholesterol levels before considering niacin

Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. Cardiovascular atherosclerosis, as it is also known, is believed responsible for one in three deaths in the United States each year.

17 Nov 2009

Sudden cardiac death more predictable in men than women

A woman who suffers sudden cardiac arrest is significantly less likely than a man to exhibit the decrease in the heart's pumping ability that is widely recognized as a precursor, says a new study in the Nov. 24 Journal of the American College of Cardiology.

17 Nov 2009

Stem cell therapy to treat heart, lung and vascular diseases show positive results

A Florida cardiologist is using stem cell therapy to treat patients who suffer from a range of heart, lung and vascular illnesses. The results have been extraordinary.

16 Nov 2009

Effect of niacin or ezetimibe added to chronic statin therapy on carotid intima media thickness: Study

In combination with statins, adding a medication that raises high-density lipoprotein (HDL) cholesterol was more effective in reversing artery wall plaque buildup and in reducing heart disease risk than adding a drug that lowers low-density lipoprotein (LDL) cholesterol, researchers reported today at the American Heart Association Scientific Sessions 2009.

16 Nov 2009

Cappella commences evaluation of the Sideguard Coronary Sidebranch Stent & Delivery System

Cappella, Inc., a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, announced the start of Sideguard 3, an IVUS/OCT evaluation of the Sideguard® Coronary Sidebranch Stent & Delivery System. This is a European multicenter study to evaluate the vascular response to Sideguard in de novo bifurcation lesions of native coronary arteries.

16 Nov 2009

Phase I clinical study for ETC-1002 commenced

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.

16 Nov 2009

UOHI to receive $5.4M federal funds for development of new alternative radioisotope imaging tracers

Researchers from the University of Ottawa Heart Institute (UOHI) will receive nearly half of a $5.4 million federal fund to help solve a shortage of medical isotopes resulting from the shutdown of the Chalk River nuclear reactor. Two research teams will develop two new alternative radioisotope imaging tracers, test new applications for their use in diagnosing heart disease, and fast track production and distribution as quickly as possible across Canada.

10 Nov 2009

NIH grants $1 million to study whether Transcendental Meditation can prevent future heart attacks in CHD patients

The National Institutes of Health's National Heart, Lung, and Blood Institute will fund a $1 million collaborative study by the Center for Natural Medicine and Prevention at Maharishi University of Management Research Institute and Columbia University Medical Center to determine whether the stress-reducing Transcendental Meditation technique can help patients with coronary heart disease (CHD) prevent future heart attacks, strokes and death.

7 Nov 2009

Stereotaxis reports $13.3 million revenue for third quarter 2009

Stereotaxis, Inc. today reported strong revenue growth, a significant increase in the gross margin, lower operating expenses and a significant reduction in the net loss for both the quarter and the nine month period ended September 30, 2009.

5 Nov 2009

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Phi Health launches high-performance MRI system at RSNA 2009

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

Vitamin D deficiency may increase risk of stroke, heart disease and death, finds study

New MEMS sensor may help clinicians distinguish stable and unstable plaque during cardiac emergencies

Vitamin D: A multi-purpose nutrient for overall health

Review of study presented at American Heart Association Scientific Sessions

Dual niacin-statin therapy improves blood cholesterol levels but does not diminish plaque buildup

Key findings from AstraZeneca's phase II studies of ticagrelor

Clinical Data commences patient enrollment in Stedivaze Phase III trial

First gene expression test for coronary artery disease

Aterovax presents results of its sPLA2 activity test in the PEACE trial

Statin therapy should still be used first to reach blood cholesterol levels before considering niacin

Sudden cardiac death more predictable in men than women

Stem cell therapy to treat heart, lung and vascular diseases show positive results

Effect of niacin or ezetimibe added to chronic statin therapy on carotid intima media thickness: Study

Cappella commences evaluation of the Sideguard Coronary Sidebranch Stent & Delivery System

Phase I clinical study for ETC-1002 commenced

UOHI to receive $5.4M federal funds for development of new alternative radioisotope imaging tracers

NIH grants $1 million to study whether Transcendental Meditation can prevent future heart attacks in CHD patients

Stereotaxis reports $13.3 million revenue for third quarter 2009

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in